← FDA DRUG APPROVALS

FDA ANDA · ANDA211278

IBUPROFEN AND FAMOTIDINE

Sponsor: TEVA PHARMS USA

APPLICATION
ANDA211278
TYPE
ANDA
ORIGINAL APPROVAL
2021-10-29
LATEST ACTION
2024-11-21
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

IBUPROFEN AND FAMOTIDINEDiscontinued
FAMOTIDINE 26.6MG, IBUPROFEN 800MG · TABLET · ORAL

Approval history

2024-11-21Labeling · Supplement 4 · standardAP
2024-10-08Labeling · Supplement 1 · standardAP
2021-10-29UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →